Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Aug;43(8):764-71.
doi: 10.1007/s00132-013-2229-3.

[Osteogenesis imperfecta]

[Article in German]
M Salzmann  1 , C Krohn, N Berger
Affiliations

[Osteogenesis imperfecta]

[Article in German]
M Salzmann et al. Orthopade. 2014 Aug.

Erratum in

  • [Erratum to: Osteogenesis imperfecta].
    Salzmann M, Krohn C, Berger N. Salzmann M, et al. Orthopade. 2015 Sep;44(9):702. doi: 10.1007/s00132-015-3151-7. Orthopade. 2015. PMID: 26296942 German. No abstract available.

Abstract

Background: Osteogenesis imperfecta (OI) is the most common genetic disease of bone and is characterized by fragile bones and growth disorders of varying severity. Most cases of OI are inherited autosomal dominant and caused by a mutation in the collagen type I gene.

Diagnostics: Indications for OI are bone fragility, stunted growth, scoliosis, skull deformities, blue sclera, loss of hearing, dentinogenesis imperfecta and increased laxity of ligaments and skin. In most cases it is possible to make a clinical diagnosis but a skin biopsy or genetic testing can be useful; however, negative results for these tests do not exclude OI.

Therapy: Therapy must be carried out in a multidisciplinary team and includes conservative (e.g. physiotherapy, rehabilitation programs and orthopedic aids), operative (e.g. intramedullary stabilization procedures) and pharmaceutical (e.g. biphosphonates and growth hormones) procedures.

Prognosis: The prognosis depends on the type of OI and ranges from normal life expectations for type 1 patients up to up to perinatal mortality for type II patients.

PubMed Disclaimer

References

    1. J Pediatr. 2006 Apr;148(4):456-60 - PubMed
    1. J Bone Joint Surg Am. 1992 Apr;74(4):598-616 - PubMed
    1. J Med Genet. 1979 Apr;16(2):101-16 - PubMed
    1. J Pediatr. 2006 Aug;149(2):174-9 - PubMed
    1. J Bone Miner Res. 2010 Jan;25(1):32-40 - PubMed

Publication types

Substances